Current status of therapeutic monoclonal antibodies against SARS-CoV-2

Sanjeev Kumar1, Anmol Chandele1, Amit Sharma2,3

1 ICGE–Emory Vaccine Center Program, International Centre for Genetic Engineering and Biotechnology, New Delhi, India, 2 Structural Parasitology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India, 3 National Institute of Malaria Research, Dwarka, New Delhi, India

* director@nimb.org

Introduction

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has taken a toll on millions of lives worldwide. Currently, India has the second highest number of active COVID-19 cases and ranks third for the total number of deaths worldwide. While few vaccines are currently approved for use in India and elsewhere, there is still an urgent need for complementary approaches to tackle the current disease burden. Human monoclonal antibodies (mAbs) that neutralize Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants provide an attractive treatment strategy. To this end, very recently, a formulation of human mAbs (casirivimab and imdevimab) against SARS-CoV-2 was approved for passive immunotherapy in mild and moderately severe COVID-19 cases in India and elsewhere. Thus, it is valuable and timely to summarize the specificity and reactivity of human mAbs against SARS-CoV-2 and its rapidly emerging variants.

Primary targets of SARS-CoV-2 therapeutic neutralizing antibodies

The spike (S) protein of SARS-CoV-2 is the primary target of neutralizing antibodies (NAbs) (Fig 1A). Therefore, NAbs against SARS-CoV-2 that have either been deployed for therapy or are in advanced stage trials, for the most part, either target the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the spike glycoprotein (Fig 1A and 1B) [1,2]. The S protein exists in different conformations within the host, and their nomenclatures are based on the position of RBD protein—an “up” or “down” position (Fig 1B). To this end, based on the epitope recognition and binding mode, RBD-specific NAbs are categorized into 4 major classes (I, II, III, and IV) [3–5]. Class I NAbs bind RBD in “up” conformation only and block ACE2 binding, whereas class II NAbs block ACE2 binding, and recognize both “up” and “down” RBDs (Fig 1B and 1C). On the other hand, the class III NAbs block ACE2 binding site, recognize spike protein with both “up” and “down” RBD conformations, and can interact with adjacent RBD protomers. The class IV NAbs do not overlap with ACE2 binding site and bind conserved region in RBD (core I region) or RBD in “up” conformation only (core II region) (Fig 1B and 1C). A complete description of these 4 classes of RBD-dependent mAbs is shown in Fig 1C.

Class II core I region-dependent NAbs have broad neutralizing activity against SARS-CoV-2, its variants, and other related coronaviruses [1–3,7]. Very recently, NAbs targeting new
epitopes on the S2 domain (stem helix region) of spike have also been identified that are broadly neutralizing, i.e., neutralize SARS-related and other human coronaviruses (hCoVs) [8–11].

**Therapeutic COVID-19 mAbs in the clinic and in clinical trials**

Therapeutic mAbs for COVID-19 treatment have been developed in accelerated time and the pace has been unprecedented for any disease. The approvals were obtained in a record time of only 10 months, including 3 to 4 months of clinical grade mAbs production since the discovery of mAbs [12]. Currently, 8 SARS-CoV-2 RBD-specific potent NAbs have been approved by the Food and Drug Administration (FDA) under an emergency use authorization (EUA) to treat COVID-19 nonhospitalized patients at high risk of severe illness. The following COVID-19 mAbs are in clinical use: bamlanivimab (LY-CoV555) [13]; bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016 or JS016) [14] from Eli Lilly; casirivimab (REGN10933) and Imdevimab (REGN10987) [15] from Regeneron; cilgavimab (COV2-2130 or AZD1061) and tixagevimab (COV2-2196 or AZD8955) [16] from AstraZeneca; monotherapy-based NAbs sotrovimab (VIR-7831) [17] from GSK and Vir Biotechnology; and regdanvimab (CT-P59) [18] from Celltrion. Another set of monotherapy and combination Nabs-based therapies are under Phase III trials: 2B04 [19] and 47D11 [20] from AbbVie; BRII-196 and BRII-198 from BRII Biosciences [2]; and TY027 from Tychan are also in Phase III trials [2]. A comprehensive list of NAbs that are currently in Phase I, II, and III trials and in clinic is summarized in Fig 2A. These therapeutic mAbs are used/administered in a range of 0.5 g to 1.2 g per dose, within 10 days of symptoms onset, as monotherapy or 2.4 g as a cocktail [21–23]. No dose-dependent effect was observed when these mAbs were tested at different doses (1.2 g to 8 g dose). The COVID-19 mAbs have demonstrated high efficacy in trials with a reduction of 70% to 85% in hospitalization or death [21,23,24]. Presently, these mAbs are used for intravenous administration; however, their intramuscular or subcutaneous administration testing is underway to facilitate larger access by overcoming the requirement of hospital settings. Presently, these mAbs are being produced in large-scale bioreactors of 15,000 L capacity, sufficient to provide 100 to 200,000 doses [12,25]. However, a single-dose regimen of these therapeutic mAbs continues to be expensive, particularly for low- and middle-income countries.

What is the efficacy of SARS-CoV-2 mAbs against emerging variants?

Several SARS-CoV-2 variants are being reported from different parts of the world. According to the World Health Organization (WHO), a recognized mutation is elevated to a “variant of concern” (VOC) when the acquisition of a new mutation allows for increased viral transmission, increased fatality, and a significant decrease in the effectiveness of therapy and vaccines. A “variant of interest” (VOI) is a variant with a new mutation capable of affecting disease severity, transmissibility, immune and diagnostic escape. The current VOCs are Alpha (B.1.1.7, identified in the United Kingdom) [26], Beta (B.1.351, identified in South Africa)
### A

| Variants of Concern (VOC) | Variants of Interest (VOI) |
|--------------------------|---------------------------|
| **mAbs**                 |                           |
| Alpha (B.1.1.7) (UK)     | Beta (B.1.351) (SA)       |
| Gamma (P.1) (Brazil)     | Delta (B.1.617.2) India   |
| Eta (B.1.526) (USA)      | Iota (B.1.526) (USA)      |
| Kappa (B.1.617.1) (India) | Lambda (C.37) (Peru)     |
| Bam                      | -                         |
| Ete                      | -                         |
| Bam+Ete                  | -                         |
| Cas                      | -                         |
| Imd                      | -                         |
| Cas/Ind                  | -                         |
| Cil                      | -                         |
| Tix                      | -                         |
| Cil/Tix                  | -                         |
| Sot                      | -                         |
| Reg                      | -                         |
| **In Clinic (EUA)**      |                           |
| Bri-I-196                | -                         |
| Bri-I-198                | -                         |
| Bri-I-190/198            | -                         |
| C135                     | -                         |
| C144                     | -                         |
| C135/C144                | -                         |
| AOG20                    | -                         |

### Phase II/III

| Variants of Concern (VOC) | Variants of Interest (VOI) |
|--------------------------|---------------------------|
| Alpha (B.1.1.7) (UK)     | Beta (B.1.351) (SA)       |
| Gamma (P.1) (Brazil)     | Delta (B.1.617.2) India   |
| Eta (B.1.526) (USA)      | Iota (B.1.526) (USA)      |
| Kappa (B.1.617.1) (India) | Lambda (C.37) (Peru)     |

### B

| Spike regions | Spike Mutations |
|---------------|-----------------|
| SP            |                 |
| L5F           |                 |
| L18F          | ✓               |
| T19R          | ✓               |
| T20N          | ✓               |
| P26S          | ✓               |
| Q65R          | ✓               |
| A67V          | ✓               |
| 69-70del      | ✓               |
| G75V          | ✓               |
| T79I          | ✓               |
| D90A          | ✓               |
| T96I          | ✓               |
| D139Y         | ✓               |
| G142D         | ✓               |
| Y144del       | ✓               |
| E154K         | ✓               |
| 157-158del    | ✓               |
| R190S         | ✓               |
| D215G         | ✓               |
| 242-244del    | ✓               |
| R246I         | ✓               |
| 246-252del    | ✓               |
| D293G         | ✓               |
| RBD           |                 |
| K417N/R       | ✓               |
| L452R/Q       | ✓               |
| T478K         | ✓               |
| E484K/Q       | ✓               |
| F490S         | ✓               |
| N501Y         | ✓               |
| SD1/SD2       |                 |
| A570D         | ✓               |
| D614G         | ✓               |
| H655Y         | ✓               |
| Q677H         | ✓               |
| P681H/R       | ✓               |
| S2            |                 |
| A701V         | ✓               |
| T716I         | ✓               |
| T895N         | ✓               |
| F988L         | ✓               |
| D950N         | ✓               |
| S982A         | ✓               |
| T1027I        | ✓               |
| Q1071H        | ✓               |
| D1118H        | ✓               |
| V1176F        | ✓               |
[27], Gamma (P.1, identified in Brazil) [28], and Delta (B.1.617.2, identified in India) [29]. The VOIs are Eta (B.1.525, identified in UK/Nigeria), Iota (B.1.526, identified in the United States of America) [30], Kappa (B.1.617.1, identified in India) [29], and Lambda (C.37, identified in Peru) [31] (Fig 2B). Recently, Epsilon (B.1.427/429, identified in the USA) [32], Zeta (P.2, identified in Brazil), and Theta (P.3, identified in the Philippines) [33] variants have been excluded from the category of VOIs by WHO due to their declining prevalence. Ideally, an effective antiviral therapeutic strategy should have the ability to prevent infection/disease by new variants while simultaneously maintaining breadth against existing multiple viral strains/variants. Recent studies have reported that many NTD-specific NAbs are relatively less effective to all emerging variants, whereas RBD-specific NAbs are variably effective against emerging variants and VOIs [2,34,35]. The majority of the potent therapeutic NAbs as monotherapy showed complete abrogation or reduced neutralizing activity against SARS-CoV-2 emerging variants that contain the E484K/Q or L452R mutations [34–37]. Bamlanivimab (LY-CoV555) was ineffective against all VOCs and thus was no longer considered for EUA. Currently, combination therapies comprising a cocktail of NAbs targeting distinct non-overlapping epitopes on RBD have demonstrated exceptional potency and promising correlates of protection against SARS-CoV-2 and its variants (Fig 2B) [36,38]. Additionally, newly identified RBD core-binding NAbs SARS2-38 [39] and LY-CoV1404 [40] as monotherapy potently neutralize all SARS-CoV-2 VOCs. Therefore, several options of NAbs targeting conserved RBD epitopes are emerging as promising and attractive therapeutic candidates to tackle the disease burden caused by SARS-CoV-2 or its variants.

Fig 2. Neutralization potential of therapeutic mAbs against SARS-CoV-2 VOCs and VOIs. (A) Neutralization potential of SARS-CoV-2 mAbs at various stages of development/clinic against VOCs and VOIs. Here, fold change represents the reduction in IC50 values of SARS-CoV-2 variant neutralization in comparison to wild-type virus. The abbreviations for mAbs in the clinic (EUA) are the following: Bam, Bamlanivimab (LY-CoV555); Ete, Etesevimab (LY-CoV016 or JS016 or CB6); Bam/Ete, Bamlanivimab+Etesevimab; Cas, Casirivimab (REGN10933); Imd, Imdevimab (REGN10987); Cas/Imd, Casirivimab+imdevimab (REGN-COV2); Cil, Cilgavimab (COV2-2130 or AZD1061); Tix, Tixagevimab (COV2-2196 or AZD8895); Tix/Cil, Tixagevimab+Cilgavimab; Sot, Sotrovimab (Vir-7831 or S309); Reg, Regdanvimab (CT-P59). (B) List of mutations present in the current SARS-CoV-2 VOCs and VOIs. EUA, emergency use authorization; mAb, monoclonal antibody; RBD, receptor-binding domain; S2, S2 subunit; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SD1, subdomain 1; SD2, subdomain 2; SP, signal peptide; VOC, variant of concern; VOI, variant of interest.

https://doi.org/10.1371/journal.ppat.1009885.g002

What is the role of antibody Fc portion in therapeutic antibodies against SARS-CoV-2?

Although anti-viral functions of NAbs against rapidly emerging variants are being studied extensively, there is also a need to focus on understanding the role of the Fc portion of NAbs in providing protection against SARS-CoV-2 and emerging variants. The role of the Fc region is secondary when NAbs are administered as prophylaxis, but is critical for optimal therapeutic protection. A recent study demonstrated that therapeutic NAbs (REGN, Abbvie, AstraZeneca, and Vir Biotechnology) with intact Fc region reduced viral load and lung disease in animal models in comparison to NAbs without Fc effector functions (LALA-PG mutation) [41]. It is well appreciated that for optimal in vivo protection, NAbs with intact Fc region can mediate downstream effector functions via interaction with Fc receptors resulting in antibody-dependent cell-mediated cytoxicity and antibody-dependent cellular phagocytosis. Moreover, Fc-mediated complement activation can exert a broad range of immunomodulatory functions, with activation of C1q resulting in antibody-mediated complement activation, and complement-dependent cytotoxicity. However, a recent study showed the diminished role of the Fc region in protecting against lethal SARS-CoV-2 infections in K18-hACE2 transgenic mice [42]. This study showed that potent NAbs do not rely on Fc effector functions to provide
optimal protection when administered as therapy. Moreover, the role of Fc-mediated antibody-dependent enhancement (ADE) observed in vitro is yet to be fully elucidated in vivo [43,44].

Benefits of multispecific antibodies

Recently, a few bispecific NAbS have been developed by combining the antibody chains of 2 independent nonoverlapping antibodies [45,46]. These bispecific NAbS neutralize wild-type SARS-CoV-2, its VOCs, and escape mutants and have shown to be protective in mice models. This suggests that bispecific NAbS are promising next-generation cost-effective therapeutics against SARS-CoV-2 and its VOCs. Such variant-resistant next-generation or combination of broadly reactive ultrapotent NAbS-based safe therapeutics are desperately needed globally. These mAb-based therapeutics should be globally accessible and affordable in low-middle income countries where more than of 85% human populations reside. Therefore, the development of a panel of well-characterized, clinically developable ultrapotent NAbS could be established rapidly to combat current and rapidly emerging SARS-CoV-2 variants.

Conclusions

Here we have summarized the current status of mAb-based therapy for COVID-19 and have shed light on the ongoing development of mAbS-based therapeutics against emerging SARS-CoV-2 variants. Due to the potential of newly emerging SARS-CoV-2 variants in the future, vaccines will need to be constantly reassessed for their efficacy. The mAb biotherapeutics are a promising strategy for immediate treatment/prophylaxis or in situations where vaccines are less effective—such as in immunocompromised individuals, young, elderly, and vaccine-hesitant individuals. MAbS can also be rapidly tailored, selected, or mined towards new variants. For this, we need more intensive studies to track viral evolution, analyze the human antibody repertoire, identify and develop pan-coronavirus NAbS that target evolutionarily conserved epitopes. These efforts will enable rapid and dynamic reconfiguration of existing NAb cocktails to cull new surges that are driven by SARS-CoV-2 variants.

References

1. Raybould MIJ, Kovaltsuk A, Marks C, Deane CM. CoV-AbDa b: the coronavirus antibody database. Bioinformatics. 2021 May 5; 37(5):734–5. https://doi.org/10.1093/bioinformatics/btaa739 PMID: 32805021
2. Tzou PL, Tao K, Nouhin J, Fhee S-Y, Hu BD, Pai S, et al. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses. 2020 Sep; 12(9):1006. https://doi.org/10.3390/v12091006 PMID: 32916958
3. Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020 Dec; 588(7839):682–7. https://doi.org/10.1038/s41586-020-2852-1 PMID: 33045718
4. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski E-SD, Fera D. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses. 2021 Jan 19; 13(1):194. https://doi.org/10.3390/v13010134 PMID: 33477902
5. Corti D, Purcell LA, Snell G, Veesseler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021 Jun 10; 184(12):3068–108. https://doi.org/10.1016/j.cell.2021.05.005 PMID: 34087172
6. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veeseler D, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16; 181(2):281–92.e6. https://doi.org/10.1016/j.cell.2020.02.058 PMID: 32155444
7. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020 Jul; 583(7815):290–5. https://doi.org/10.1038/s41586-020-2349-y PMID: 32422645
8. Song G, He W, Callaghan S, Anzanello F, Huang D, Rickets J, et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021 May 19; 12(1):2938. https://doi.org/10.1038/s41467-021-23074-3 PMID: 34011939
9. Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun. 2021 Mar 17; 12(1):1715. https://doi.org/10.1038/s41467-021-21968-w PMID: 33731724

10. Sauer MM, Tortorici MA, Park Y-J, Walls AC, Homd L, Acton OJ, et al. Structural basis for broad coronavirus neutralization. Nat Struct Mol Biol. 2021 May; 12:1–9.

11. Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, et al. A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery. bioRxiv. 2021 May 10. https://doi.org/10.1101/2021.05.09.442808

12. Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020 May; 38(5):540–5. https://doi.org/10.1038/s41587-020-0512-5 PMID: 32317764

13. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. JAMA. 2021 Mar 2; 325(9):880–1. https://doi.org/10.1001/jama.2020.24415 PMID: 33306087

14. An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther. 2021 Apr 5; 63(1621):49–50. PMID: 33830966

15. An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther. 2020 Dec 28; 62(1614):201–2. PMID: 33451174

16. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021 Mar 1. https://doi.org/10.1101/2021.01.27.428529 PMID: 33532768

17. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021 May 13. https://doi.org/10.1101/2021.03.09.434607

18. Kim C, Ryu D-K, Lee J, Kim Y-I, Seo J-M, Kim Y-G, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021 Jan 12; 12(1):288. https://doi.org/10.1038/s41467-020-20602-5 PMID: 33436577

19. Alsoussi WB, Turner JS, Case JB, Zhao H, Schmitz AJ, Zhou JQ, et al. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020 Aug 15; 205(4):915–22. https://doi.org/10.4049/jimmunol.2000583 PMID: 32591393

20. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 May 4; 11(1):2251. https://doi.org/10.1038/s41467-020-16256-y PMID: 32366817

21. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med [Internet]. 2020 Oct 28 [cited 2021 Jun 7]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2029849 PMID: 33113295

22. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Feb 16; 325(7):632–44. https://doi.org/10.1001/jama.2021.0202 PMID: 33475701

23. Weinreich DM, Sivapalasingam S, Norton T, Al S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med [Internet]. 2020 Dec 17 [cited 2021 Jun 7]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2035002 PMID: 33332778

24. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falcì DR, et al. Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. medRxiv. 2021 May 28. https://doi.org/10.1101/2021.05.27.21257096

25. Kelley B, Renshaw T, Kamarch M. Process and operations strategies to enable global access to antibody therapies. Biotechnol Prog. 2021; 37(3):e3139. https://doi.org/10.1002/btpr.3139 PMID: 33686779

26. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis [Internet]. 2021 Apr 12 [cited 2021 Aug 3]. Available from: https://www.thelancet.com/journals/laninf/article/Piis1473-3099(21)00170-5/abstract https://doi.org/10.1016/S1473-3099(21)00170-5 PMID: 33857406

27. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020 Dec 22. https://doi.org/10.1101/2020.12.21.20248640
28. Voloch CM, da Silva FR, de Almeida LGP, Cardoso CC, Brustolini OJ, Gerber AL, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol. 2021 Mar 1. https://doi.org/10.1128/JVI.00119-21 PMID: 33649194

29. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021 Jul; 27(7):1131–3. https://doi.org/10.1038/s41591-021-01397-4 PMID: 34045737

30. West AP, Wertheim JO, Wang JC, Vasylyeva TI, Chowdhury MA, et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. bioRxiv. 2021 Apr 22. https://doi.org/10.1101/2021.02.14.431043 PMID: 33907745

31. Wink PL, Volpato FCZ, Monteiro FL, Willig JB, Zavascki AP, Barth AL, et al. First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. medRxiv. 2021 Jun 23. https://doi.org/10.1101/2021.06.21.21259241

32. McCallum M, Bassi J, Marco AD, Chen A, Walls AC, Iuliano JD, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. 2021 Apr 1. https://doi.org/10.1101/2021.03.31.437925 PMID: 33821281

33. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations, and immune escape. Nat Rev Microbiol. 2021 Jul; 19(7):409–24. https://doi.org/10.1038/s41579-021-00573-0 PMID: 34075212

34. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021 Apr; 27(4):717–26. https://doi.org/10.1038/s41591-021-01294-w PMID: 33664494

35. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 May; 593(7857):130–5. https://doi.org/10.1038/s41586-021-03398-2 PMID: 33684923

36. Diamond M, Chen R, Winkler E, Case J, Aziati I, Bricker T, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Res Sq. 2021 Apr 23.

37. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv. 2021 May 27. https://doi.org/10.1101/2021.05.26.445838

38. Liu H, Yuan M, Huang D, Bangaru S, Zhao F, Lee C-CD, et al. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 May 12; 29(5):806–18. e6. https://doi.org/10.1016/j.chom.2021.04.005 PMID: 33894127

39. VanBlargan LA, Adams LJ, Liu Z, Chen RE, Gilchuk P, Raja S, et al. A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. bioRxiv. 2021 Apr 26. https://doi.org/10.1101/2021.04.26.441501 PMID: 33907753

40. Westendorf K, Žentelis S, Foster D, Vaillancourt P, Wiggin M, Lovett E, et al. LY-CoV1404 potently neutralizes SARS-CoV-2 variants. bioRxiv. 2021 May 4. https://doi.org/10.1101/2021.04.30.442182 PMID: 33972947

41. Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 Apr 1; 184(7):1804–20. e16. https://doi.org/10.1016/j.cell.2021.02.026 PMID: 33691139

42. Noy-Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, et al. Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies. bioRxiv. 2021 May 15. https://doi.org/10.1101/2021.05.15.443978

43. Li D, Edwards RJ, Manne K, Martinez DR, Schäfer A, Alam SM, et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv. 2021 Feb 18. https://doi.org/10.1101/2020.12.31.424729 PMID: 33442694

44. Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021 Feb 2; 34(5):108699. https://doi.org/10.1016/j.celrep.2021.108699 PMID: 33485405

45. De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksf F, Cassaniti I, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021 May; 593(7859):424–8. https://doi.org/10.1038/s41586-021-03461-y PMID: 33767445

46. Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, et al. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv. 2021 Apr 1. https://doi.org/10.1101/2021.04.01.437942 PMID: 33821267